News and Updates

Minneapolis (February 22, 2017) - Coloplast, a global medical device company and leader in intimate healthcare needs, has been awarded a group purchasing agreement for Wound Care and Skin Care with Premier Inc. effective April 1, 2017.  This new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Coloplast Wound and Skin Care Products.

“We are extremely honoured that Premier Inc. has once again chosen to partner with Coloplast for Wound and Skin Care.  Coloplast shares Premiers core values to improve patient outcomes and provide value to its customers,” said Thomas Vigso, Vice President, US Wound and Skin Care at Coloplast. 

The agreement is effective for three years beginning April 1, 2017.  Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,750 U.S. hospitals and 130,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions,  advisory and other services, Premier enables better care and outcomes at a lower cost.

About Coloplast Skin Care
Coloplast manufactures and distributes a broad portfolio of US made skin care products that cleanse, moisturize, and protect against skin breakdown and other forms of skin damage. Coloplast products can be used by patients of all ages from neonate to geriatric and are comprised of minimal ingredients and can be used as part of a simplified formulary.

Coloplast products include the unique Bedside-Care® EasiCleanse™ bathing solution, the market leading InterDry® moisture-wicking fabric with antimicrobial silver, as well as the established Sween® 24 once-a-day moisturizing body cream and Critic-Aid® Clear moisture barrier ointment.

About Coloplast Wound Care
Coloplast manufactures a broad portfolio of Advanced Wound Care products that can be used across the full spectrum of wounds and patients.  

Coloplast Products include the Biatain® Silicone wound dressing, Comfeel® Hydrocolloid dressing, Biatain® Alginate, Biatain® Super Absorbent dressing and the Physiotulle® contact layer.

About Coloplast
Danish medical device company Coloplast develops products and services designed to make life easier for people with very personal and private medical conditions. Coloplast listens to end-users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions.  www.coloplast.us/about-coloplast. 

Coloplast’s businesses include ostomy care, urology care, continence care,  wound and skin care. For four consecutive years, Coloplast has received global recognition for having the best corporate reputation among patients (PatientView, 2012-15), twice for Most Ethical (Ethisphere Institute, 2012-13) and also the Most Sustainable (StoreBrand Bank) company. 

US press contact:

Brian Israel
Phone: 651.485.3420
Mail: bisrael@beehivepr.biz

Global press contact:

Maria Lindeberg, Senior Media Relations Manager
Phone: 00 45 49 11 30 95
Mail: dkmalg@coloplast.com

Coloplast employees donate their time to serve and support Habitat for Humanity Central Arizona​.

Minneapolis, (Minnesota, November 3-, 2016) — During the National Sales Meeting in Scottsdale, AZ this November the Coloplast North America Chronic Care worked with the Habitat for Humanity Central Arizona​ to refresh the Restore building in Mesa, Arizona.

 The Restore building is a non-profit home improvement and donation center that is open to the public and sells new and gently used furniture, appliances, home accessories, building material and more. . . at a fraction of the retail price.

 A habitat home, like ones built with materials from the Restore locations, helps families achieve the self-reliance they need to build a better life.

 "Making a difference in #affordablehousing, makes a difference in someone’s life," Angela Robey, Senior Marketing Communications Manager, at Coloplast said. "This goes hand in hand with Coloplast’s mission of making life easier for people with intimate healthcare needs. By coming together as a team and living our values, we are able to support the Central Arizona community."

 Habitat for Humanity brings people together to build homes, communities and hope. They envision a world where everyone has a decent place to live.

 You can visit the Habitat for Humanity Central Arizona website at the link below for more information.

http://habitatcaz.org/

About Coloplast

Danish medical device company Coloplast develops products and services designed to make life easier for people with very personal and private medical conditions. Coloplast starts by listening to the users to better understand their needs, and then responds by bringing the best ideas to market in the form of medical devices and service solutions.

Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. For four consecutive years, Coloplast has received global recognition for having the best corporate reputation among patients (PatientView, 2012-15), twice for being the Most Ethical (Ethisphere Institute, 2012-13) and also for being the Most Sustainable (StoreBrand Bank) company.

US press contact:

Brian Israel
Phone: 651.485.3420
Mail: bisrael@beehivepr.biz

Global press contact:

Maria Lindeberg, Senior Media Relations Manager
Phone: 00 45 49 11 30 95
Mail: dkmalg@coloplast.com

Comfort Medical is a privately owned, US direct-to-consumer Durable Medical Equipment (DME) nationwide dealer of catheters and ostomy supplies founded in Florida in 2010. The acquisition is a continuation of Coloplast’s ambition to bring innovative products and services to the US market.

“The acquisition of Comfort Medical fits very well into our overall consumer ambition for Coloplast in the US, securing continued access to innovative technology for end users. Comfort Medical has a strong patient acquisition model and an efficient and scalable setup in addition to a strong management team with a good cultural fit to Coloplast,” says Lars Rasmussen, Coloplast’s CEO.

Comfort Medical’s business model is based on capturing patients through Direct Response Advertisement and physician referrals. Comfort Medical provides patients with products from a number of different manufacturers including Coloplast. The company is expected to record sales of USD 38m or approx. DKK 270m for the full-year 2016.

“I am excited about the future prospects of our US business and view this acquisition as an additional building block in the implementation of our US strategy,” Lars Rasmussen says.

The transaction is expected to contribute to Coloplast’s long-term growth ambition and is expected to close in the first quarter of 2016/17. The acquisition will, if completed and approved by authorities, lead to a revised financial guidance for the financial year 2016/17:

• The organic revenue growth guidance of 7-8% is unchanged. The growth in DKK of 5-6% is expected to be 1-2%-points higher.
• The EBIT margin guidance of 33-34% in constant exchange rates and about 33% in DKK is unchanged.
• The long-term guidance of 7-9% organic growth p.a. and an EBIT margin expansion of 0.5%-1.0%-points p.a. is unchanged.

About Coloplast

Danish medical device company Coloplast develops products and services designed to make life easier for people with very personal and private medical conditions. Coloplast starts by listening to the users to better understand their needs, and then responds by bringing the best ideas to market in the form of medical devices and service solutions.

Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. For four consecutive years, Coloplast has received global recognition for having the best corporate reputation among patients (PatientView, 2012-15), twice for being the Most Ethical (Ethisphere Institute, 2012-13) and also for being the Most Sustainable (StoreBrand Bank) company.

US press contact:

Brian Israel
Phone: 651.485.3420
Mail: bisrael@beehivepr.biz

Global press contact:

Maria Lindeberg, Senior Media Relations Manager
Phone: 00 45 49 11 30 95
Mail: dkmalg@coloplast.com

Coloplast ranks among top 100 most innovative companies for 2016  

Minneapolis, Minnesota, September 12, 2016 — Coloplast, a Minneapolis-based medtech company that develops products and services to treat intimate healthcare needs, has been named to Forbes magazine’s 2016 list of the World’s 100 Most Innovative Companies. This is the fourth consecutive year that Coloplast has been honored, moving up 11 spots to number 22 on this year’s rankings.

“Innovation is in Coloplast’s DNA,” said Edmond Veome, senior vice president of Coloplast U.S. “Our entire organization is focused on developing our products to make life easier for users with intimate healthcare needs.”

 Coloplast produces a broad range of medical equipment such as ostomy bags, catheters, urology products and wound care items. Working closely with the people who use the product, the company creates innovative solutions to meet their individual, personal needs.

 Forbes ranking system includes in-depth financial and market evaluation based on a firm’s “innovation premium”. In order to be eligible for ranking on the list, companies are also required to have seven years of public financial data and between $2-10 billion in market value. For the full rankings list, visit Forbes.

About Coloplast

Danish medical device company Coloplast develops products and services designed to make life easier for people with very personal and private medical conditions. Coloplast starts by listening to the users to better understand their needs, and then responds by bringing the best ideas to market in the form of medical devices and service solutions.

Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. For four consecutive years, Coloplast has received global recognition for having the best corporate reputation among patients (PatientView, 2012-15), twice for being the Most Ethical (Ethisphere Institute, 2012-13) and also for being the Most Sustainable (StoreBrand Bank) company.

US press contact:

Brian Israel
Phone: 651.485.3420
Mail: bisrael@beehivepr.biz

Global press contact:

Maria Lindeberg, Senior Media Relations Manager
Phone: 00 45 49 11 30 95
Mail: dkmalg@coloplast.com

Coloplast Receives Supplier Horizon Award from Premier Inc.  

Minneapolis, Minnesota, July 07, 2016 - Coloplast today announced that it is a winner of Premier Inc.’s Supplier Horizon Award.

One of 12 suppliers to receive the award this year, Coloplast was recognized for its support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs.

“We are very pleased Premier has chosen Coloplast as one of the Supplier Horizon Award recipients. This award recognizes our efforts in providing Premier members support, through our products and services, that align with our mission of making life easier for those with intimate healthcare needs” said Ed Veome, Sr. Vice President, North America Chronic Care.

Coloplast accepted the award at Premier’s 2016 Breakthroughs Conference and Exhibition on June 22.

“Coloplast supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said Durral R. Gilbert, president of supply chain services, Premier. “We’re honored to recognize them as a Horizon Award recipient.”

About Premier Inc.
Premier Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com for more information about the company.

About Coloplast
Danish medical device company Coloplast develops products and services designed to make life easier for people with very personal and private medical conditions. Coloplast starts by listening to the users to better understand their needs, and then responds by bringing the best ideas to market in the form of medical devices and service solutions.

Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. For four consecutive years, Coloplast has received global recognition for having the best corporate reputation among patients (PatientView, 2012-15), twice for being the Most Ethical (Ethisphere Institute, 2012-13) and also for being the Most Sustainable (StoreBrand Bank) company.

US press contact:
Brian Israel
Phone: 651.485.3420
Mail: bisrael@beehivepr.biz

Global press contact:
Maria Lindeberg, Senior Media Relations Manager
Phone: 00 45 49 11 30 95
Mail: dkmalg@coloplast.com

Minneapolis (September 15, 2015)—Coloplast announced the U.S. launch of SpeediCath^® Compact Male, the most compact catheter for men, designed so users can do more. The new product is less than half the size of a standard male catheter and may be stored, carried, used and disposed of more discreetly. The SpeediCath Compact Male all-in-one design is instantly ready to use, featuring “no touch” insertion and withdrawal that provides a level of convenience and is usable anywhere, anytime.

Every day, more than half of all men aged 50+ face problems emptying their bladder due to various health conditions, primarily linked to their prostate. A challenge they share with the growing number of people living with Spinal Cord Injury. Not being able to urinate naturally, many men have to insert a catheter, which can be up to 15 inches long, through the urethra 4-6 times a day.

Storing, using and transporting catheters this size is hard to do discreetly. The lack of discretion around their catheters is an important issue for many users. Coloplast has developed a revolution in catheter design to meet that need. SpeediCath Compact Male comes in a discreet and compact package that is easily concealed, allowing for patients to feel more relaxed and free to do what they want. The new device also comes pre-lubricated with a unique, hydrophilic coating and polished eyelets designed for comfortable and simple catheterization no matter where they are. These innovative SpeediCath Compact Male features open up exciting, new possibilities for its users, eliminating lifestyle limitations and enhance their quality of life compared to standard catheter use.

“Coloplast is focused on developing products that make life easier for people with very personal and private medical conditions,” said Erik Greene, Coloplast Product Manager, Continence Care. “When we designed SpeediCath Compact Male, we listened to and learned from the people who use our products that discretion was the most important feature. This product is a solution that meets their personal need, and comes ready to use for even greater convenience and discretion. SpeediCath Compact Male gives men a level of comfort and ease that they can use it at home or on the go. We are proud to bring this unique intimate healthcare product to users in the US.”

Patient Feedback

End user feedback has been positive. A 2011 Product Evaluation study found that 96% of users described SpeediCath Compact Male as discreet. One patient, Dan, said, “Out of curiosity, I tried SpeediCath® Compact Male and things have improved dramatically. When I do go out, you would never know I have the catheters in my pocket.”

Patients will also be pleased to know SpeediCath® Compact Male not only is discreet, but it also is perfect for home or on the go. A 2011 Product Evaluation study found that 85% of patients felt the product easy to use.

###

About Coloplast
Coloplast develops products and services designed to make life easier for people with very personal and private medical conditions. We start by listening to our users to better understand their needs, and then respond by bringing the best ideas to market in the form of medical devices and service solutions. Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. With the development of a strong portfolio of new products and investments in a professional sales force, Coloplast now employs more than 10,000 people worldwide. For four consecutive years (2012-2015), Coloplast has received global recognition for having the best corporate reputation among patients (PatientView).

About Coloplast Continence Care

Coloplast Continence Care provides product innovations for conditions affecting bladder and bowel functions. Our products include Self-Cath®, the first disposable intermittent catheter, SpeediCath, the world’s first ready-to-use hydrophilic-coated catheter and the first self- adhesive male external catheter. Coloplast also developed industry-leading Coloplast Care, a nurse-directed care program that supports the patient from the healthcare setting to their transition home and through their lifetime. Providing wellness education, lifestyle tips, product information and service, the Coloplast Care program is yet another way Coloplast makes life easier for people living with intimate healthcare needs, and the health care professionals that support them.

Learn more about Coloplast

PRESS CONTACT U.S.

Brian Israel

Public Relations

+1 651.789.2238

bisrael@beehivepr.biz

PRESS CONTACT OUTSIDE U.S.
Dennis Kaysen

Senior Communication Consultant

+45 4911 2608

dkdk@coloplast.com

Coloplast has been rated the best medical device company in a survey by the independent research organization PatientView. 

 Coloplast has the best reputation among the industry's 28 leading medical device companies, according to a survey by the independent British research organization PatientView. A total of 463 patient organizations in 58 countries were surveyed about their views on 28 medical device companies. The US represented 8.9% of the patient groups.

 Coloplast emerged as the overall winner for the fourth straight year and takes the top spot in four of six indicators. Coloplast was ranked ahead of competitors like Medtronic (3rd place), St. Jude Medical (4th) and ConvaTec (5th).

 The survey measures the reputation of the medical device industry overall, and respondent patient groups were asked to rate each company in terms of six indicators:

• Does the company have an effective patient-centered strategy?
• Does the company provide high-quality information for patients?
• The company's record on patient safety
• Are the products useful to patients?
• The company's record of transparency with external stakeholders
• Does the company act with integrity?

Recognition by the users

“Historically, users have been at the center of what we do at Coloplast, and we have a strong ambition to create impactful improvements in the lives of people who use our products in the US. To us the best kind of recognition is that from our users and we're proud and very excited to be given this recognition for the fourth straight year,” said Ed Veome, Senior Vice President, Chronic Care US.

Mr. Veome continued: "We're pursuing a strategy that puts the consumer in the center and we want to deliver innovative, discreet products and services that make the everyday lives of our users easier. We can only do that by listening to their needs and involving them in our product innovation”.

About Coloplast

Coloplast employs more than 500 people in the US and has its US headquarter in Minneapolis, Minnesota. Coloplast develops products and services that make life easier for people with very personal and private medical conditions. The four major business areas are ostomy care, urology and continence care and wound and skin care.

Globally, Coloplast employs more than 10,000 with its products being sold in more than 100 countries around the world. Coloplast is listed on the Copenhagen Stock Exchange, part of the NASDAQ OMX Group.

The 463 respondent patient groups cover a wide range of specializations, including neurology, cancer, diabetes and mental health. The largest contingent (10.2%) were from Germany, 9.5% were from Spain while 9.3% were from the UK and 8.9% of the patient groups were from the US.  The survey was conducted in the period from March to June 2015.

The survey measures the reputation of the medical device industry among the respondent patient groups, who were asked to rate each company in terms of six indicators:

• Does the company have an effective patient-centered strategy?
• Does the company provide high-quality information for patients?
• The company's record on patient safety
• Are the products useful to patients?
• The company's record of transparency with external stakeholders
• Does the company act with integrity?

 For further information, please contact:

Simon Mehl Augustesen

Senior Manager, Media Relations

Tlf. 4911 3488

dksia@coloplast.com

This FDA approval reinforces Coloplast’s commitment to prosthetic urology and advancing the surgical technique of prosthetic surgery,” said Eric Halvorson, Coloplast Global Vice President and General Manager, Urology Care. “The clinical community expressed a need for ectopic reservoir placement, and can be confident about using the new surgical procedure with our innovative product.”  

Impact on the Clinical Community

Peer-reviewed publications supporting the new procedure indicate that 90% of high-volume prosthetic surgeons believe placing the reservoir in an ectopic location can be advantageous for patient safety1. In addition, Abdominal Wall/ATF (Anterior to Tranversalis Fascia) placement of an IPP reservoir is seen as a relatively simple technique that can avoid the possibility of catastrophic complications associated with traditional retroperitoneal reservoir placement1.

“Catastrophic bowel, bladder and vascular injuries related to inflatable penile implant reservoir placement can be tragic for everyone involved in a procedure,” explained Dr. Paul Perito, Chief of Surgery at Coral Gables Hospital (Fla.). “Coloplast’s efforts to gain approval for urologists to choose abdominal wall reservoir placement over traditional placement in the retropubic space has provided the necessary vehicle to drastically reduce the risk of these catastrophic injuries for patients.”

Dr. Allen Morey, Professor, Department of Urology, University of Texas Southwestern Medical Center in Dallas (Texas), added, “Reservoir placement has long been one of the primary challenges of prosthetic urology, due to the neighboring vital structures encountered both placing and removing reservoirs deep in the pelvis. The submuscular abdominal wall reservoir location offers a safe alternative strategy with reduced risk of injury to surrounding pelvic organs. We have found submuscular abdominal wall placement to be well tolerated by patients and easy to teach and perform.” 

Improving Patient Life

The new surgical treatment option is an advantageous development for patients considering an IPP to help manage erectile dysfunction (E.D.). Approximately 30 million men suffer from E.D.2, and nearly one in every four men over sixty-five will experience some degree of the condition3. Coloplast’s Men’s Health products put men back in charge by restoring reliability and spontaneity to their lives and relationships. 

“Coloplast delivers solutions for those with intimate healthcare needs – we work very closely with the people who use our products improve their quality of life,” said Halvorson. 
The Titan family of IPPs represents the next generation of innovation, and are designed to emulate the look and performance of a natural erection. These products have been developed in Coloplast’s long standing tradition of listening and responding to customers, offering a dependable method of restoring sexual function.

For more information on the newly approved abdominal wall placement procedure for the Titan IPPs and other solutions that are available to treat E.D., visit www.coloplastmenshealth.com.

###

1. Doron S. Stember, MD, Bruce B. Garber, MD, and Paul E. Perito, MD. Outcomes of Abdominal Wall Reservoir Placement in Inflatable Penile Prosthesis Implantation: A Safe and Efficacious Alternative to the Space of Retzius. J Sex Med 2014;11:605–612

2. NIHConsensStatement1992Dec7-9;10(4):1-31. 

3. NIH Publication No. 09-3923. June 2009. 

About Coloplast 

Danish medical device company Coloplast develops products and services designed to make life easier for people with very personal and private medical conditions. We start by listening to our users to better understand their needs, and then respond by bringing the best ideas to market in the form of medical devices and service solutions. Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. With the development of a strong portfolio of new products and investments in a professional sales force, Coloplast now employs more than 8,500 people worldwide. In 2013, Coloplast received global recognition for having the best corporate reputation among patients (PatientView). 

About Coloplast Surgical Urology

Coloplast Urology produces a range of surgical devices to help people who suffer from urological disorders such as erectile dysfunction (E.D.), urinary incontinence, weak pelvic muscles, kidney stones and enlarged prostates. We have two focus areas: Female Pelvic Health and Men’s Pelvic Health. Both are dedicated to developing devices that can make life easier for people suffering from intimate urological disorders. Coloplast is in continuous dialogue with surgeons and nurses to improve less invasive surgical therapies for male and female incontinence. We are always working to constantly improve our products and streamline other surgical implant procedures.
To learn more about Coloplast, visit www.us.coloplast.com.

PRESS CONTACT U.S.

Brian Israel

Public Relations

+1 651.789.2238

bisrael@beehivepr.biz

SenSura® Mio provides a better fit to individual bodies. The elastic barrier is specifically designed to follow the contours of the body. The response from a recent survey is clear: 90% of clinicians say that the elastic barrier follows individuals' body movements better than their current product. 

Learn more about the new SenSura Mio here

Minneapolis (January 13, 2015)—Coloplast today announced clinician and user preference for the new SenSura® Mio, according to a 2014 product evaluation comparing ostomy pouching systems. 96 percent of surveyed clinicians said they would recommend Coloplast SenSura Mio for use in their hospital while 90 percent of clinicians reported SenSura Mio’s elastic barrier has a better fit and follows patient body movements better than their current product.

“Insecurity and lack of discretion are two important and well-documented obstacles for people with an ostomy, and we have worked hard in our innovation and design teams to come up with an answer to those challenges. We are proud to be able to listen and respond with a product designed with individual bodies in mind to make a positive change for those living with an ostomy” said Anders Holm, Coloplast Ostomy Care Vice President.

Survey Results

The U.S. product evaluation was conducted between February and May 2014 among 497 clinicians and 213 people living with an ostomy. Clinicians and users were asked to compare Coloplast SenSura Mio with their current products from Coloplast, ConvaTec and Hollister.

Clinicians

• 90 percent of clinicians reported SenSura Mio’s elastic barrier follows patients’ body movements better than their current product.
• 90 percent of clinicians found SenSura Mio’s elastic barrier fits to body shapes better than the current product.
• 81 percent of clinicians reported SenSura Mio improved the overall patient experience.
• 96 percent of clinicians said they would recommend their hospital use SenSura Mio.

Ostomy Patients    

• 90 percent of patients found the SenSura Mio pouch offers very good or good discretion.
• 89 percent of patients said the SenSura Mio elastic barrier has a very good or good fit to the body.
• 86 percent of patients found the SenSura Mio elastic barrier is very good or good at following body movements.

The New SenSura Mio

SenSura Mio uses BodyFit™ Technology to provide patients with a greater sense of security. Coloplast recognizes no two bodies are the same and their abdomen and body shape changes during the course of the day. The SenSura Mio elastic barrier is designed to fit individual bodies and follow its contours and movements throughout the day to maintain a secure seal.

SenSura Mio is also the first ostomy pouch to be produced in a  soft all-textile material, similar to clothing, to give it a personal discreet look and feel. The neutral gray fabric provides increased discretion by allowing the pouch to blend in and go unnoticed under all clothing colors. 

In addition to the barrier technology and the neutral gray fabric, SenSura Mio also offers a unique new full-circle filter that provides greater protection against ballooning.  In a recent survey 78% of users said the filter on the new SenSura Mio is better than their current product.

The new SenSura Mio launched in May 2014 and is available to patients across the U.S. For more information or to request a free trial visit www.sensuramio.us.

About Coloplast
Coloplast is a global medical device company that develops products and services designed to make life easier for people with very personal and private medical conditions. We start by listening to our users to better understand their needs and then respond by bringing the best ideas to market in the form of medical devices and service solutions. Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. With the development of a strong portfolio of new products and investments in a professional sales force, we now employ more than 9,000 people worldwide. In 2012 and 2013, Coloplast received global recognition for having the best corporate reputation among patients (PatientView), and for being the Most Ethical (Ethisphere Institute) and Most Sustainable (StoreBrand Bank) company. Coloplast is also a finalist for the PM360 Trailblazer Medical Device Company of the Year award, which recognizes achievement in innovation, talent development and social responsibility.  

About Coloplast Ostomy Care

Coloplast Ostomy Care provides products for conditions affecting bladder and bowel functions. This includes innovations to make life easier such as the skin-friendly benefits of SenSura, easy-to-use no-sting Brava^® accessory products to protect and care for the skin, and the new BodyFit™ elastic barrier technology that fits to real bodies. Coloplast also developed industry-leading Coloplast Care, a nurse-directed care program that supports the patient from the healthcare setting to their transition home and through their lifetime. Providing wellness education, lifestyle tips, product information and service, the Coloplast Care program is yet another way Coloplast makes life easier for people living with intimate healthcare needs, and the healthcare professionals that support them.

To learn more about the new SenSura Mio, click here.

PRESS CONTACT U.S.

April Nelson

651-789-2249

anelson@beehivepr.biz

PRESS CONTACT OUTSIDE U.S.
Dennis Kaysen

Senior Communication Consultant

+45 4911 2608

dkdk@coloplast.com

Coloplast's Urology Care business, the smallest of the company's three legs, will be continuing its globalization strategy of recent years. The company expects to keep outperforming market growth over the next few years. The goal is to almost double the business, which would also lift profitability by quite a big margin.

“We are now ready to quantify our targets. Our ambition, and what we are shooting for, is the DKK 2bn mark in revenue. It is a target we need to reach as quickly as possible,” said Steffen Hovard, Senior Vice President of Coloplast's Urology Care business, at a press meeting held at Coloplast's US headquarters in Minneapolis.

Coloplast takes first place in a new global survey – in front of large international competitors such as Johnson & Johnson and Smith & Nephew – in which more than 400 patient groups around the world evaluated 30 medtech companies’ ability to meet patient expectations.

In a new global study carried out among 412 patient groups from 39 different countries Coloplast is ranked at the very top in front of large international competitors such as Johnson & Johnson and Smith & Nephew. It is the second year in a row that Coloplast is ranked as the best medtech company by patient groups.

In total, the patient groups have ranked 30 medtech companies on six indicators. Coloplast is ranked highest on each of the indicators.

Strong customer focus 
”We are both glad and proud that so many customers from all over the world believe that Coloplast is the best medtech company. I believe it is an expression of the fact that we are truly making a difference for the people around the world that need our help”, says Senior Vice President for Global Marketing in Coloplast, Nicolas Nemery. He adds:

”Our products address critical needs but if you ask our customers they would prefer to live a life where they wouldn’t need them. That’s why we make it a priority for our products to be reliable and intuitive and make sure that our customers get the guidance they need. We are committed to understand our customers and have always worked closely together with them and involved them in the development of our products. I believe that is the reason that we for the second year in a row have been ranked as the best medtech company”.

PatientView, an independent research organization, conducted the survey in March 2013.

Coloplast’s results 
A total of 38 patient groups have evaluated Coloplast in the survey. These particular groups represent a broad spectrum of chronic diseases, including cancer, urinary and gastrointestinal diseases.

The participating patient groups were asked to assess medtech companies' abilities on six indicators (Coloplast’s position in brackets):

1.     Whether the company has an effective patient-centered strategy        (1^st )

2.     The quality of the information that the company provides to patients (1^st )

3.     The company’s record on patient safety                                            (1^st )

4.     The usefulness of the company’s products to patients                      (1^st )

5.     Record of transparency with external healthcare stakeholders            (1^st )

6.     Whether the company acts with integrity                                            (1^st )

Background
The study was conducted and funded by PatientView, an independent global research organization with close ties to patient and health groups worldwide, in March 2013. The study results express the views of more than 400 patient and health groups regarding 30 individual medtech companies and the medtech industry as a whole.

Participating patient groups were required to know enough about the pharmaceutical companies and industry to assess them meaningfully.

About Coloplast
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 8,000 people.

Contact

Simon Augustesen

Media Relations Manager

+45 4911 3488

dksia@coloplast.com

In addition to providing funds for building materials, Coloplast volunteers will work side by side with future Habitat homeowners to construct simple, decent, affordable homes for hard working, low-income individuals in Southern Nevada.  The project, while still in its early stages, will eventually house six deserving families, with an estimated completion date of June 2014. Two of the homes have recently been finished and all properties will be Energy Star and WaterSmart certified.

“Habitat for Humanity’s continuing efforts to strengthen the Las Vegas community are needed now more than ever to stabilize struggling families,” said Meg Delor, Executive Director, Habitat for Humanity Las Vegas. “With every new family that moves in with ambitions to create a better life, Southern Nevada becomes a safer, more vibrant place to call home. Coloplast volunteers are more than just a group of people contributing their time to construct a house. They are helping build a community that learns how teamwork can fulfill dreams. Bridges are built between people, as well as the satisfaction of being part of a life changing experience."

"Coloplast’s North American Urology Care team is excited to work alongside the Las Vegas Habitat for Humanity program and be able to engage both teamwork and energy for such a positive endeavor," says Joel Chechik, Vice President of Sales, Coloplast Corporation. We’ve dedicated almost 600 “person hours” for philanthropic outreach during our company meeting (in Las Vegas) and were delighted that Habitat for Humanity (Las Vegas) could utilize such a resource.  I’m proud that our ten Regional Managers will lead their respective teams and drive this massive effort to ultimately achieve substantial progress in several homes, in just one day.  The Coloplast Urology Care team has a great sense of pride in our daily interactions. However, the work with Habitat for Humanity is beyond special – as a team, we will visualize the very difference we can all make."  

About Habitat for Humanity Las Vegas

Established in Clark County in 1991, Habitat for Humanity Las Vegas is a not-for-profit organization that builds simple, decent, affordable housing with the help of volunteer labor, donated funds, time and materials.  Each home is sold at no profit and with a no-interest mortgage to local working families who otherwise might be forced to live in substandard housing.  These families contribute “sweat equity” by helping in the construction of their own homes.  For more information, visit www.habitatlasvegas.org, ‘like’ us on Facebook at facebook.com/habitatlasvegas and follow us on Twitter @habitatlasvegas.  Habitat for Humanity Las Vegas has received a 4-Star rating from Charity Navigator, America's largest and most-utilized independent evaluator of charities.

About Coloplast

Coloplast is a global medical device company that develops products and services designed to make life easier for people with very personal and private medical conditions. We start by listening to our users to better understand their needs and then respond by bringing the best ideas to market in the form of medical devices and service solutions. Coloplast’s businesses include ostomy care, urology care, continence care, and wound and skin care. With the development of a strong portfolio of new products and investments in a professional sales force, we now employ more than 8,000 people worldwide. In 2012 and 2013, Coloplast received global recognition for having the best corporate reputation among patients (PatientView), and for being the Most Ethical (Ethisphere Institute) and Most Sustainable (StoreBrand Bank) company. Coloplast is also a finalist for the PM360 Trailblazer Medical Device Company of the Year award, which recognizes achievement in innovation, talent development and social responsibility.